Compare · ABBV vs ALKS
ABBV vs ALKS
Side-by-side comparison of AbbVie Inc. (ABBV) and Alkermes plc (ALKS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and ALKS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $401.47B, about 56.3x ALKS ($7.13B).
- Over the past year, ABBV is up 17.4% and ALKS is up 38.5% - ALKS leads by 21.1 points.
- ALKS has been more active in the news (18 items in the past 4 weeks vs 10 for ABBV).
- Both have 25 recent analyst ratings on file.
- Company
- AbbVie Inc.
- Alkermes plc
- Price
- $221.94-2.27%
- $43.13+0.77%
- Market cap
- $401.47B
- $7.13B
- 1M return
- +9.53%
- +21.80%
- 1Y return
- +17.41%
- +38.55%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2012
- 1991
- News (4w)
- 10
- 18
- Recent ratings
- 25
- 25
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Alkermes plc
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia; and VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI (olanzapine/samidorphan), an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; a license agreement with Acorda Therapeutics, Inc.; and a license and collaboration agreement with Biogen Swiss Manufacturing GmbH. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Latest ABBV
- AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
- AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
- SEC Form SD filed by AbbVie Inc.
- AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia
- FDA Approval for DECNUPAZ issued to ABBVIE INC
- U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options
- SEC Form 144 filed by AbbVie Inc.
- AbbVie Announces Positive CHMP Opinion for MAVIRET® (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection
- AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline
- Allergan Aesthetics Receives Positive CHMP Opinion for Boey® (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults
Latest ALKS
- EVP, CLO, Alkermes, Inc. Gaffin David Joseph sold $87,564 worth of Ordinary Shares (2,034 units at $43.05) as part of a pre-agreed trading plan, decreasing direct ownership by 0.88% to 229,524 units (SEC Form 4)
- Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
- Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
- EVP R&D, Chief Medical Officer Hopkinson Craig C. sold $375,044 worth of Ordinary Shares (9,000 units at $41.67) as part of a pre-agreed trading plan and exercised 5,000 units of Ordinary Shares at a strike of $19.34, decreasing direct ownership by 5% to 77,389 units (SEC Form 4)
- VP, Finance (Interim PAO) Parisi Samuel Joseph sold $687,007 worth of Ordinary Shares (16,217 units at $42.36) and exercised 16,217 units of Ordinary Shares at a strike of $19.48 (SEC Form 4)
- Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
- Director Wright Christopher I converted options into 6,142 units of Ordinary Shares and covered exercise/tax liability with 1,475 units of Ordinary Shares, increasing direct ownership by 20% to 27,680 units (SEC Form 4)
- Director Wilson Frank Anders covered exercise/tax liability with 1,475 units of Ordinary Shares and converted options into 6,142 units of Ordinary Shares, increasing direct ownership by 15% to 35,751 units (SEC Form 4)
- Director Snyderman Nancy Lynn Md converted options into 6,142 units of Ordinary Shares and covered exercise/tax liability with 1,475 units of Ordinary Shares, increasing direct ownership by 44% to 15,395 units (SEC Form 4)
- Director Mckeon Brian P converted options into 6,142 units of Ordinary Shares and covered exercise/tax liability with 1,475 units of Ordinary Shares, increasing direct ownership by 14% to 38,536 units (SEC Form 4)